The recently announced Nissha – USM Healthcare transaction is drawing attention – not only as a healthcare M&A deal, but also as a clear example of how global supply chains are being restructured across Asia.
In this article, Vilasia’s Ngu Truong and Nam Trinh examine the transaction beyond its surface, highlighting how strategic considerations – including “China Plus One”, technology integration, and CDMO expansion – are shaping investment decisions in Vietnam’s medical device sector.
Through a detailed analysis of valuation approaches, regulatory considerations, and post-M&A integration challenges, the article shows how investors are increasingly pricing future growth potential rather than current financial performance, while also navigating a multi-layered legal and compliance framework.
The article also offers practical insights for Vietnamese companies engaging with Japanese investors, from due diligence expectations to transaction structuring and post-deal governance.
The article was originally published in Vietnamese in The Saigon Times on April 2, 2026.
